CN1099286C - 福斯高林在制备治疗酒精成瘾的药物中的应用 - Google Patents

福斯高林在制备治疗酒精成瘾的药物中的应用 Download PDF

Info

Publication number
CN1099286C
CN1099286C CN96194036A CN96194036A CN1099286C CN 1099286 C CN1099286 C CN 1099286C CN 96194036 A CN96194036 A CN 96194036A CN 96194036 A CN96194036 A CN 96194036A CN 1099286 C CN1099286 C CN 1099286C
Authority
CN
China
Prior art keywords
forskolin
treatment
alcohol
ethanol
alcohol addiction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96194036A
Other languages
English (en)
Other versions
CN1184422A (zh
Inventor
P·莫拉佐尼
E·鲍姆巴德利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Publication of CN1184422A publication Critical patent/CN1184422A/zh
Application granted granted Critical
Publication of CN1099286C publication Critical patent/CN1099286C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

本发明涉及福斯高林和含有福斯高林的提取物在治疗酒精成瘾中的应用。

Description

福斯高林在制备治疗酒精成瘾的药物中的应用
本发明涉及治疗酒精成瘾的药物组合物，其特征在于它们含有作为有效成分的福斯高林或含它的提取物。
酒精滥用和酒精成瘾是可以统称为酒精中毒的现象，它代表整个现代社会一种严重的难题(Gessa G.L.， Bisogno compulsivo di bere e “principio del piacere”[对饮酒的强迫需要和快乐原则]，Medicinadelle tossicodipendenze[药物成瘾医学]II，5(1994))。例如，在意大利重度酗酒者超过人口的9％(大约为5百万人)，并且酒精成瘾者超过1百万(Calamo-Specchia F.P.， Epidemiologia dell alcolismo in Italia[意大利酒精中毒的流行病学]，Atti del VII Congresso Nazionaledella S.I.A.[第7届S.I.A.全国大会记录]Mediserve，罗马，295-301，(1991))。如果考虑到诸如美国等国家，这些数字更高，在美国酒精成瘾者超过1千3百万。酒精滥用和酒精成瘾可导致社会资金的巨大浪费(最近报道，自1991年以来在美国每年花费大约200,000,000,000美元)，并且还可引起所卷入的个体巨大的社会和心理损害。
除了那些心理本性疗法(群体疗法等)，现存治疗酒精中毒的方法在于使用诸如戒酒硫和氨基甲酸钙的药物，它们在每次饮酒出现各种不需要的现象的时候对酒精的代谢起作用，抑制肝脏醛脱氢酶，由此升高血的乙醛水平。
按照本领域目前的状况，衍生物已经用于治疗酒精中毒的唯一植物是葛根(葛根)，它在中医中广泛应用，并构成专利申请WO 93/00896的主题。
现在已经惊喜的发现福斯高林可成功地用于减少酒精和其他可引起成瘾的药物的自主消耗。
福斯高林，即17-β-乙酰氧基-8，13-环氧-1α，6β，9α-三羟基化-14-环-11-酮，其式为：它是从产于印度的植物Coleus forskohlii中分离的一种双萜，它可激活腺苷酸环化酶。
De Souza和Shah在《经济和药用植物研究》第2卷，H.Wagner，H.Hihiho和N.Farusuworth等，学术出版社，1988中描述了它的药理学活性。
已知福斯高林可用于治疗心血管和呼吸系疾病以及青光眼；例如在一篇综述中可见到上面的引证；如Seamon和Daly在Adv.Cycli Nucleotide Res.20，1中所述。
应用称为“撒丁岛酒精偏爱”(Sp)系的消耗酒精鼠对酒精消耗的抑制作用进行测定(Fadda F.，Mosca E.，Colombo G.，Gessa G.L.，酒精偏爱鼠：乙醇诱导的多巴胺代谢的刺激作用的遗传敏感性，Physiol.Behav.47，727(1990))。
在最近这些年中，已经成功地应用这些动物对不同物质对酒精自主消耗的作用进行了测定，使它们在酒精和水消耗之间进行自由选择，每天每公斤体重给6至7g酒精(水对酒精的比例大于2∶1)；例如，见：BalakleevskyA.，Colombo G.，Fadda F.，Gessa G.L.在 《Ro19-4603，一种苯并二氮 杂卓受体反兴奋剂可减小选择性喂养的对高酒精偏爱的鼠自主酒精消 耗》，Alcohol Alcohol.25，449-452(1990)中以及Fadda F.，GarauB.，Colombo G.，Gessa G.L.在 《伊拉地平和其他钙通道拮抗剂减小酒精 偏爱鼠的酒精消耗》，酒精中毒：临床和实验研究16(3)，449-452(1992)中所述。
将这些动物保持在正常的喂养条件下，在水(总是存在)和酒精(一种10％v/v的溶液)之间对它们进行自由选择，其中酒精一天供给4小时(即：在白天/夜晚循环中，黑暗的头4小时)。在每天的同一时间记录所消耗的水和酒精的量。任意供给食物。一旦酒精和水的消耗稳定下来，则口服给予溶解在二甲亚砜中剂量为50mg/kg的福斯高林，其给药的容积量为2ml/kg，一天一次，连续7天。相同量的载体作为对照。在治疗末记录酒精和水的消耗，直到重建治疗前所记录的值。
附图1A显示50mg/kg福斯高林重复口服给药对酒精消耗的影响；附图1B显示对水的影响。
从附图1的实验中可以得到这样的结论，福斯高林可明显地减小酒精消耗。此酒精消耗的减小保持不变，这样直到第7天，然后随着治疗的中止，此减小出现倒退。而且还惊奇地注意到，这种趋势伴随着水消耗逐渐升高的趋势，好象此动物用水代替了酒精。此后者的观察特别重要，这是因为它表明用所实验的产物进行的治疗被极好的耐受，并且动物在没有任何困难的情况下，通过用水代替酒精返回到一种更加生理化的生活周期。
因此本发明所提供的药物组合物可进行口服给药，并且含有作为有效成分的福斯高林。除了常用的赋形剂或载体，本发明的组合物可含有大约10至500mg的这种有效成分。实施例1 香粉制剂每2,300mg香粉含有：福斯高林                                 100mg蔗糖                                     2,000mg麦芽糊精                                 110mg柠檬酸                                   30mg桔橙香料                                 40mg氢化植物油                               20mg实施例2 药片制剂每100mg片剂含有：福斯高林                                    25mg微晶纤维素                                  25mg乳糖                                        37mg胶体硅                                      1mg交联羧基甲基纤维素钠                        6mg聚乙烯吡咯烷酮                              5mg硬脂酸镁                                    1mg

Claims (1)

1.福斯高林在制备治疗酒精成瘾的药物中的应用。
CN96194036A 1995-05-19 1996-05-09 福斯高林在制备治疗酒精成瘾的药物中的应用 Expired - Fee Related CN1099286C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI951023A IT1275436B (it) 1995-05-19 1995-05-19 Uso della forskolina e di estratti che la contengono per il trattamento della alcol-dipendenza
ITMI95A001023 1995-05-19

Publications (2)

Publication Number Publication Date
CN1184422A CN1184422A (zh) 1998-06-10
CN1099286C true CN1099286C (zh) 2003-01-22

Family

ID=11371634

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96194036A Expired - Fee Related CN1099286C (zh) 1995-05-19 1996-05-09 福斯高林在制备治疗酒精成瘾的药物中的应用

Country Status (18)

Country Link
US (1) US5902823A (zh)
EP (1) EP0825859B1 (zh)
JP (1) JP3001641B2 (zh)
KR (1) KR100423486B1 (zh)
CN (1) CN1099286C (zh)
AT (1) ATE215368T1 (zh)
AU (1) AU697449B2 (zh)
CA (1) CA2221592C (zh)
DE (1) DE69620394T2 (zh)
DK (1) DK0825859T3 (zh)
ES (1) ES2175099T3 (zh)
HK (1) HK1005651A1 (zh)
HU (1) HU223474B1 (zh)
IT (1) IT1275436B (zh)
NO (1) NO316054B1 (zh)
PT (1) PT825859E (zh)
RU (1) RU2183455C2 (zh)
WO (1) WO1996036332A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2298142C (en) 1997-07-30 2005-07-12 Indena S.P.A. Soya extract, process for its preparation and pharmaceutical composition
EP1645272A3 (en) * 1998-05-12 2008-11-05 The Endowment For Research In Human Biology, Inc. Daidzin derivatives for the treatment of alcohol dependence or alcohol abuse
US20060122261A1 (en) * 2003-11-20 2006-06-08 Muhammed Majeed [method of preparing labdane diterpene composition, preferably isoforskolin and deacetylforskolin from forskolin extract and their use for promoting lean body mass and other applications]
US20100144885A1 (en) * 2006-09-29 2010-06-10 The Board Of Trustees Of The University Of Illinois Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366990A (en) * 1991-11-14 1994-11-22 Reid Larry D Method for treating alcohol abuse and alcoholism
US5371104A (en) * 1989-03-08 1994-12-06 Feigenbaum; Jeffery J. Compositions containing forskolin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4120975A (en) * 1976-08-26 1978-10-17 Fisons Limited Method of psychiatric conditions
US4782082A (en) * 1982-12-27 1988-11-01 Schering Corporation Method for treating allergic reactions with Forskolin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371104A (en) * 1989-03-08 1994-12-06 Feigenbaum; Jeffery J. Compositions containing forskolin
US5366990A (en) * 1991-11-14 1994-11-22 Reid Larry D Method for treating alcohol abuse and alcoholism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIFE SCIENCE,VOL.42,NO.6,1988 1988-01-01 SZABO"Forkolin promotes the development of ethanol tolerance in 6-hydroxydopam-ine-treated mice" *

Also Published As

Publication number Publication date
CA2221592C (en) 2002-07-09
CN1184422A (zh) 1998-06-10
ES2175099T3 (es) 2002-11-16
JP3001641B2 (ja) 2000-01-24
KR19990014876A (ko) 1999-02-25
NO316054B1 (no) 2003-12-08
IT1275436B (it) 1997-08-07
JPH11500738A (ja) 1999-01-19
ITMI951023A0 (it) 1995-05-19
EP0825859A1 (en) 1998-03-04
DE69620394T2 (de) 2002-10-02
ITMI951023A1 (it) 1996-11-19
NO975155D0 (no) 1997-11-10
WO1996036332A1 (en) 1996-11-21
HK1005651A1 (en) 1999-01-22
US5902823A (en) 1999-05-11
AU5816396A (en) 1996-11-29
HUP9801236A3 (en) 2001-09-28
HUP9801236A2 (hu) 2000-06-28
NO975155L (no) 1997-11-10
HU223474B1 (hu) 2004-07-28
DK0825859T3 (da) 2002-07-29
PT825859E (pt) 2002-08-30
RU2183455C2 (ru) 2002-06-20
DE69620394D1 (de) 2002-05-08
AU697449B2 (en) 1998-10-08
CA2221592A1 (en) 1996-11-21
ATE215368T1 (de) 2002-04-15
KR100423486B1 (ko) 2004-06-05
EP0825859B1 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
DE60226103T2 (de) Heilnahrungsmittel
US5547671A (en) Anti-intoxication composition
TW200904461A (en) A pharmaceutical composition for treating depression and method for preparation thereof
Gill et al. Effects of serotonin uptake blockade on food, water, and ethanol consumption in rats
CA2290458A1 (en) Use of isoflavonoids in the treatment or prevention of postpartum depression
CN1099286C (zh) 福斯高林在制备治疗酒精成瘾的药物中的应用
CA1273874A (en) Appetite moderating and anti-gastritis composition
KR20070070307A (ko) 수면 개선 의약 조성물
CN1066336C (zh) 治疗酒精成瘾的药物组合物
KR101362539B1 (ko) 과민성방광 증후군 예방 및 치료용 조성물
WO1999061028A1 (en) Isoflavonoids for treatment and prevention of migraine headaches
US20040202677A1 (en) Method of enhanced regional body fat reduction
Cohen Therapeutic aspects
WO2021213502A1 (zh) 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物
Bereda Catha Edulis Forsk and its adverse effects on health: current and ongoing factuality
CN102552236A (zh) 丹参酮i治疗小胶质细胞介导的疾病的用途
Ranga et al. General introduction of shankhpushpi according to ayurveda
Jakhar A Review Study on Nutritional and Medicinal Importance of Lemon
KR102623362B1 (ko) 녹용 발효물을 유효성분으로 포함하는 여성 갱년기 증상의 예방, 개선 또는 치료용 조성물
JP2006131572A (ja) 月経関連症状の緩和剤
CN1814148A (zh) 一种治疗前列腺炎的中药组合物及其应用
CN112999218A (zh) 一种具有镇静助眠功效的组合物及用途
CN112402485A (zh) 植物提取物在抗产褥期精神综合症药物中的应用
CN115025173A (zh) 一种含大麻二酚cbd提取物用于辅助睡眠药物应用
CN118240668A (zh) 一株白檀菌及其在制备治疗抑郁症药物上的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20030122

Termination date: 20100509